Chelsea Therapeutics International (Nasdaq: CHTP) $2.43. Today announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, in combination with carbidopa has been initiated in adult attention deficit hyperactivity disorder (ADHD).
ADHD is a neurobiological disorder characterized by lifelong issues of inattention, distraction, organizational difficulties, forgetfulness, restlessness, and other disruptive behavioral issues. ADHD is the second most common neuropsychiatric disorder affecting 4.4% of the U.S. adult population, or between 8-9 million individuals. As adult ADHD is characterized as a disorder of decreased norepinephrine (NE) activity in the pre-frontal cortex, it is hypothesized that by limiting the peripheral metabolism of Droxidopa into NE through co-administration of carbidopa, the enhanced central levels of Droxidopa may have a positive therapeutic effect in adult ADHD.
What They Do: Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases.
Cardtronics (Nasdaq: CATM) $12.12. Today announced its financial and operational results for the quarter and year ended December 31, 2009. Consolidated revenues of $124.8 million, up 6% from the fourth quarter of 2008. Revenue growth of approximately 8% for the Company's core business operations, which include the Company's domestic company-owned large-account ATM placement and branding business and the Company's international operations.
Gross margins of 31%, up considerably from 24% in the fourth quarter of 2008. Adjusted EBITDA of $27.6 million, up more than 44% from $19.1 million in the fourth quarter of 2008. Adjusted Net Income per Share of $0.17, up from $0.02 in the fourth quarter of 2008. GAAP Net Income of $1.5 million compared to a $58.5 million GAAP Net Loss in the fourth quarter of 2008.
What They Do: Cardtronics is the world's largest non-bank owner of ATMs. Cardtronics operates over 33,400 ATMs across its portfolio, with ATMs in every major market in the United States and Puerto Rico, over 2,600 ATMs throughout the United Kingdom, and over 2,600 ATMs throughout Mexico.
Wonder Auto Technology (Nasdaq: WATG) $9.60. Today announced its financial results for the fourth quarter and full year ended December 31, 2009. Sales revenue increased 49.5% year-over-year to a record $211.0 million.Gross profit rose 41.0% year-over-year to $51.4 million. Net income attributable to Wonder Auto increased 20.9% year-over-year to $22.9 million. Non-GAAP EPS was $ 0.86 for the full year 2009, compared with Non-GAAP EPS $0.73 in 2008.
What They Do: Wonder Auto Technology, Inc., through its Chinese subsidiaries, designs, develops, manufactures and sells automotive electrical parts, suspension products and engine components.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
